

Supplementary Table 1: Demographics and presentation comparing intermediate risk patients with or without a common bile duct stone image on cholangiogram					
		Total (N=399)	CBD stone (N=50)	No CBD stone (N=349)	P value
Intermediate risk		N=126	N=29	N=97	
Gender	Male, No. (%)	51 (40.5%)	8 (27.6%)	43 (44.3%)	.107
	Female, No. (%)	75 (59.5%)	21 (72.4%)	54 (55.7%)	
Age (mean ± SD), years		53 ± 21	46 ± 24	55 ± 20	.058
BMI (mean ± SD), kg/m ²		28 ± 5	30 ± 6	27 ± 5	.05
Clinical presentation	Fever, No. (%)	13 (10.3%)	1 (3.4%)	12 (12.4%)	.166
	RUQ pain on admission, No. (%)	108 (85.7%)	23 (79.3%)	85 (87.6%)	.261
	Associated cholecystitis, No. (%)	86 (68.3%)	16 (55.2%)	70 (72.2%)	.085
Admission LFTs (mean ± SD)	ASAT, IU/L		219 ± 194	87 ± 116	.002
	ALAT, IU/L		243 ± 222	92 ± 139	.002
	PA, IU/L		162 ± 113	90 ± 52	.003
	GGT, IU/L		332 ± 308	122 ± 181	.002
	Total Bilirubin, µmol/L		32 ± 19	23 ± 14	.017
	Conjugated Bilirubin, µmol/L		20 ± 10	11 ± 8	.006
Abnormal admission LFTs	ASAT (11-42 IU/L), No. (%)	49 (38.9%)	3 (10.3%)	46 (47.4%)	< .001
	ALAT (9-42 IU/L), No. (%)	52 (41.3%)	3 (10.3%)	49 (50.5%)	< .001
	PA (30-125 IU/L), No. (%)	91 (72.2%)	15 (51.7%)	76 (78.4%)	.005
	GGT (9-35 IU/L), No. (%)	35 (27.8%)	1 (3.4%)	34 (35.1%)	< .001
	Total Bilirubin (7-25 µmol/L), No. (%)	75 (59.5%)	13 (44.8%)	62 (63.9%)	.066
	Conjugated Bilirubin (2-9 µmol/L), No. (%)	27 (21.4%)	3 (10.3%)	24 (24.7%)	.097

BMI = Body Mass Index, RUQ = Right Upper Quadrant, CBD = Common Bile Duct, LFTs = Liver Function Tests, SD = Standard Deviation.

ASAT = Aspartate Aminotransferase, ALAT = Alanine Aminotransferase, PA = Alkaline Phosphatase, GGT = Gamma-glutamyl Transferase.